Freedom Investment Management Inc. Decreases Position in DexCom, Inc. $DXCM

Freedom Investment Management Inc. cut its position in DexCom, Inc. (NASDAQ:DXCM) by 6.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 3,991 shares of the medical device company’s stock after selling 295 shares during the period. Freedom Investment Management Inc.’s holdings in DexCom were worth $348,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Golden State Wealth Management LLC raised its holdings in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 264 shares during the last quarter. Zions Bancorporation National Association UT purchased a new position in shares of DexCom during the first quarter valued at approximately $27,000. Anderson Financial Strategies LLC purchased a new position in shares of DexCom during the first quarter valued at approximately $37,000. Private Trust Co. NA raised its holdings in shares of DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 335 shares during the last quarter. Finally, Horizon Financial Services LLC purchased a new position in shares of DexCom during the first quarter valued at approximately $56,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on DXCM. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 10th. Morgan Stanley boosted their price objective on shares of DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Canaccord Genuity Group restated a “buy” rating and set a $106.00 target price on shares of DexCom in a research report on Monday, September 29th. Mizuho boosted their target price on shares of DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. Finally, William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $97.19.

DexCom Price Performance

DXCM stock opened at $70.33 on Monday. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25. The company’s fifty day moving average price is $72.37 and its 200-day moving average price is $77.98. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The company has a market capitalization of $27.58 billion, a PE ratio of 48.84, a price-to-earnings-growth ratio of 1.48 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, Director Mark G. Foletta sold 2,750 shares of the company’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director owned 51,121 shares of the company’s stock, valued at $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the sale, the executive vice president directly owned 105,223 shares in the company, valued at approximately $8,417,840. The trade was a 1.37% decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,383 shares of company stock worth $434,274 in the last ninety days. Company insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.